B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
about
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyTherapeutic regulation of complement in patients with renal disease - where is the promise?Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.Mycophenolic acid differentially impacts B cell function depending on the stage of differentiation.Longevity of SLE-prone mice increased by dietary 2-mercaptoethanol via a mechanism imprinted within the first 28 days of life.Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.ESRD from lupus nephritis in the United States, 1995-2010Diabetes tolerogenic vaccines targeting antigen-specific inflammationB-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.B-cell-depleting therapy in systemic lupus erythematosus.The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness.In vivo detection of peripherin-specific autoreactive B cells during type 1 diabetes pathogenesis.Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?Treatment of proliferative lupus nephritis: a slowly changing landscape.Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus.Lupus arthritis--do we have a clinically useful classification?Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets.Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus.Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.Biologic therapies in systemic lupus erythematosus.B cells biology in systemic lupus erythematosus-from bench to bedside.Recent advances and current state of immunotherapy in systemic lupus erythematosus.Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up.Thirty years, five hundred patients: some lessons learned from running a lupus clinic.Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients-a potential biomarker of disease activity.Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
P2860
Q24633214-9D52C188-17F9-45D6-A29A-8A35BAD455E2Q26851705-1807529E-2510-4950-B4B4-259A442B61B7Q33407247-CF7BCE4D-FF07-4D9D-8B79-ECFFD8C11D1AQ34267100-CC7A080E-5959-40A4-94A6-92A2158821A7Q34775743-511A12A2-34CC-4B47-B848-501B04735271Q34979203-FAB0710C-784A-40E1-B243-D36D2539E5B2Q35051164-8545C1C7-B9D0-4579-90C3-A36CE8931978Q35887037-E4D0BFF1-DC6D-40AA-8845-521AE93DA873Q36049625-EAC400BD-F004-44C6-BD92-7E0DE9B83459Q37586344-425C6185-7D70-436A-8BF9-0A87C7C4EC53Q37627356-1FF38B4B-1337-4C1A-B05C-5D184BF2B146Q37714655-05C07AF6-7CF3-455B-AA29-B16821D189D6Q37814530-E95F3656-DA9B-47A2-9469-2ADA65FEC965Q37822658-65407EDE-F304-4A19-A199-DD936EB622F1Q37884384-E8A7AE67-0B48-497C-A27A-F6CA60BB9101Q37954539-0317B0C7-6A37-4F52-97F1-4C47F65F2151Q37960525-59B40E3A-7E52-45D7-8558-ACFB66B2100CQ37969656-0C55EA96-B44F-44F0-9E0F-FD496D94F514Q38108851-AE85E4BE-DF9F-41C8-90D2-B81EDCF3241DQ38153509-CE701160-14D3-4D28-9BC0-00C180061ECBQ38309470-54979334-CF4A-44D0-9033-F77FB59ED95DQ38408710-B14BD0E9-5C93-43E1-BEFA-C45484E681F7Q38425831-A7B4D044-E043-4109-A72E-2816C3D3125FQ38631964-79075103-13B6-45B9-97C2-5C4E17C56CA6Q38794663-33AAFA7F-758E-4C96-A836-475FE02D705DQ42694406-EA36C4E6-8999-4AEB-A07E-5A4AADACEEF5Q48878229-B13A064E-47BC-4184-8810-BC2EF4F73E11Q51067608-31E730D0-3B19-4172-AFEF-C857A91677F8Q51386995-5D713E38-9801-4F13-835C-4366E1B4E484
P2860
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
@en
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
@nl
type
label
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
@en
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
@nl
prefLabel
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
@en
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
@nl
P356
P1476
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?
@en
P2093
Catarina Favas
David A Isenberg
P2888
P304
P356
10.1038/NRRHEUM.2009.218
P407
P577
2009-12-01T00:00:00Z